1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,880 | 2,960 | 11:53 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 24.09. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 15.09. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 08.09. | HAOHAI BIOTEC (06826): INTERIM REPORT 2025 | - | HKEx | ||
| 05.09. | Dividendenbekanntmachungen (05.09.2025) | 12.440 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AAON INC US0003602069 0,1 USD 0,0858 EUR ACUSHNET HOLDINGS CORP US0050981085 0,235 USD 0,2017 EUR AIA GROUP LTD HK0000069689 0... ► Artikel lesen | |
| 22.08. | HAOHAI BIOTEC (06826): DISTRIBUTION AND PAYMENT OF 2025 INTERIM DIVIDEND AND CLOSURE OF REGISTER OF MEMBERS | 1 | HKEx | ||
| 22.08. | HAOHAI BIOTEC (06826): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025 | - | HKEx | ||
| 12.08. | HAOHAI BIOTEC (06826): DATE OF BOARD MEETING | - | HKEx | ||
| 28.07. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 30.06. | HAOHAI BIOTEC (06826): ANNOUNCEMENT ON ADJUSTMENT OF SHARE PRICE CAP FOR REPURCHASE OF A SHARES | 3 | HKEx | ||
| 10.06. | HAOHAI BIOTEC (06826): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 10.06. | HAOHAI BIOTEC (06826): WORKING RULES OF THE NOMINATION COMMITTEE OF THE BOARD | - | HKEx | ||
| 10.06. | HAOHAI BIOTEC (06826): WORKING RULES OF THE REMUNERATION AND APPRAISAL COMMITTEE OF THE BOARD | - | HKEx | ||
| 10.06. | HAOHAI BIOTEC (06826): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 10.06. | HAOHAI BIOTEC (06826): WORKING RULES OF THE AUDIT COMMITTEE OF THE BOARD | - | HKEx | ||
| 10.06. | HAOHAI BIOTEC (06826): ELECTION OF CHAIRMAN OF THE BOARD; CHANGE OF COMPOSITION OF BOARD COMMITTEES AND APPOINTMENT OF SENIOR MANAGEMENT AND SECURITIES ... | 1 | HKEx | ||
| 10.06. | HAOHAI BIOTEC (06826): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2024 (UPDATED) | 2 | HKEx | ||
| 10.06. | HAOHAI BIOTEC (06826): POLL RESULTS OF ANNUAL GENERAL MEETING, A SHAREHOLDERS' CLASS MEETING AND H SHAREHOLDERS' CLASS MEETING; 2024 PROFIT DISTRIBUTION; ... | 1 | HKEx | ||
| 27.05. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 09.05. | HAOHAI BIOTEC (06826): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2024 (UPDATED) | - | HKEx | ||
| 09.05. | HAOHAI BIOTEC (06826): PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE ABOLISHMENT OF THE SUPERVISORY COMMITTEE | 1 | HKEx |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 4,456 | -0,40 % | Valneva korrigiert Finanzziele - Hoffnung bleibt auf Lyme-Impfstoff ab 2027 | Valneva hat eine neue Kreditfazilität über bis zu 500 Millionen US-Dollar mit von Pharmakon Advisors verwalteten Fonds abgeschlossen. Eine erste Tranche von 215 Millionen US-Dollar dient zur vollständigen... ► Artikel lesen | |
| AMGEN | 250,30 | +0,14 % | Amgen Launches AmgenNow, Direct-to-patient Program; Available To Repatha Patients | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha or evolucumab. Repatha will be available through AmgenNow at a... ► Artikel lesen | |
| STRYKER | 315,10 | +0,35 % | Stryker to roll out training center model in Ireland with first in Limerick | ||
| REGENERON PHARMACEUTICALS | 486,80 | +0,16 % | FDA Approves Regeneron's Libtayo As Adjuvant Therapy For High-Risk Skin Cancer Patients | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) announced that the U.S. Food and Drug Administration has approved its PD-1 inhibitor, Libtayo (cemiplimab-rwlc), as an adjuvant treatment... ► Artikel lesen | |
| EXACT SCIENCES | 49,895 | -0,67 % | Piper Sandler raises Exact Sciences stock price target to $70 on Cologuard growth | ||
| CSL | 117,38 | +0,22 % | CSL Behring Canada Signs LOI With PCPA For Public Reimbursement Of HEMGENIX | CANBERA (dpa-AFX) - CSL Behring Canada Inc., a unit of CSL Ltd. (CMXHF.PK), Monday announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA)... ► Artikel lesen | |
| BEONE MEDICINES LTD ADR | 284,00 | +2,90 % | BeOne Medicines price target raised to $362 from $259 at Bernstein | ||
| CANSINO BIOLOGICS | 5,275 | +3,74 % | CANSINOBIO (06185): REVISED FORM OF PROXY FOR USE AT THE 2025 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, OCTOBER 23, 2025 | ||
| SINO BIOPHARM | 0,790 | +1,28 % | Aktienmarkt: Aktie von Sino Biopharmaceutical tritt auf der Stelle (0,88 €) | Wenig Kursbewegung zur Stunde bei der Sino Biopharmaceutical-Aktie . Das Wertpapier notiert aktuell bei 0,88 Euro. Ein geringes Minus von 5,12 Prozent zeigt die Kurstafel für die Aktie von Sino Biopharmaceutical... ► Artikel lesen | |
| BIOMERIEUX | 115,70 | +1,22 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| ZAI LAB LTD ADR | 26,600 | +1,53 % | Zai Lab Limited: Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 | -Data highlights potential of ZL-1503 as a promising treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases -Favorable preclinical safety profile, prolonged... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,760 | +3,40 % | CSTONE PHARMA-B (02616): INTERIM REPORT 2025 | ||
| CASI PHARMACEUTICALS | 2,100 | +0,96 % | CASI Pharmaceuticals Appoints James Huang to Board of Directors | - Industry veteran brings over 35 years of biotech experience as a successful entrepreneur and investor- Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb)... ► Artikel lesen | |
| 3SBIO | 3,020 | +1,34 % | Pfizer Completes Licensing Agreement With 3SBio For Cancer Drug | NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) Thursday said it has completed the licensing agreement with 3SBio, Inc. for exclusive rights to develop and sell 3SBio's SSGJ-707.As per the deal... ► Artikel lesen | |
| GENSCRIPT BIOTECH | 1,800 | -0,99 % | GenScript Biotech Corporation: GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation | Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation
PISCATAWAY, N.J., Aug. 17, 2025 /PRNewswire/ --... ► Artikel lesen |
Das Unternehmen SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO LTD finden Sie auf Wallstreet Online.